US Health Agency Calls for Inquiry into Alzheimer's Drug Review
Voice of America
WASHINGTON - The acting head of the Food and Drug Administration on Friday called for a government investigation into highly unusual contacts between her agency's drug reviewers and the maker of a controversial new Alzheimer's drug.
Dr. Janet Woodcock announced the extraordinary step via Twitter. It's the latest fallout over last month's approval of Aduhelm, an expensive and unproven therapy that the agency OK'd against the advice of its own outside experts. Woodcock made the request to the Department of Health and Human Services' inspector general, the watchdog agency that oversees the FDA and other federal health agencies. The move comes after numerous calls for a probe into the approval from medical experts, consumer advocates and members of Congress. Two congressional committees have already launched their own review. "We believe an independent assessment is the best manner in which to determine whether any interactions that occurred between the manufacturer and the agency's review staff were inconsistent with FDA's policies and procedures," Woodcock wrote on Twitter. Biogen pledged to cooperate with the inquiry.Director Lou Ye is pictured during a photo call for the film "An Unfinished Film," presented as part of Special Screenings at the 77th Cannes Film Festival in Cannes, France, May 17, 2024. From left, producer Philippe Bober, producer Yingli Ma, director Lou Ye, actor Hao Qin and actor Huang Xuan are pictured during a photo call for "An Unfinished Film" at the Cannes Film Festival in France, May 17, 2024. FILE - Chinese artist Ai Weiwei takes pictures in front of his pieces displayed during the press preview for the exhibition "Ai Weiwei: Making Sense" at the Design Museum in London, April 4, 2023. FILE - In this May 30, 2019, photo, a computer screen shows web content from outside China, including a clip of Chinese singer Li Zhi singing his song "The Square."